肾细胞癌诊断治疗指南-肾之友网 R11例(19.3%),SD36例(63.16%),疾病控制率达84.21%,中位PFS时间41周,中位总生存期(overall survival,OS)未达。3-4级毒副反应包括手足皮肤反应(16.1%),腹泻(6.45%),高血压(12.9%),白细
基于12个网页-相关网页
...com豆丁网 同质性.这几项研究均提供了中位无进展生 存期(progress-freesurvival,PFS)、中位总生存期(overallsurvival,OS), 但是因为无法获得每项研究的所有病人的个人资料,所以无法对这两项指标进 行Meta-分析.所以用于...
基于4个网页-相关网页
1年生存率为40.0%,中位总生存期(median overall survival,mOS)和中位无进展生存期(median progression free survival,mPFS)分别...
基于4个网页-相关网页
随访中位总生存期 overall survival ; OS
但中位总生存期,次要观察终点,联合组为20.5个月,而单药治疗组为20.6个月。
But median overall survival, a secondary end point, was 20.5 months in the combination group and 20.6 months in the monotherapy group.
结论:我们对边缘区淋巴瘤的研究是已报道的研究中规模最大的之一,结论是边缘区淋巴瘤总体预后良好,中位总生存期超过19年。
Conclusions: In our MZL series, one of the largest reported, prognosis of MZL is good with a median OS of over 19 years.
结果:在33个被评估的病人中,总的反应率为70%(完全反应率加未确定的完全反应率,45%),中位无进展生存期为16.5个月。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
应用推荐